New monoclonal antibody drug could combat antimicrobial resistance
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
List view / Grid view
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
New research uncovers how neutrophils trigger cellular processes to counteract the Candida albicans toxin.
Using computational screening, researchers have discovered an antibiotic called Dynobactin, that halts the advance of antibiotic-resistant bacteria.
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
In a pre-clinical study, researchers from the US set out to develop a treatment for sepsis. Here, Daniel Morales-Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, describe how they utilised haematopoietic stem and progenitor cell infusion to improve the survival of mice from sepsis.
This ebook includes a piece by Daniel Morales- Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, on a stem and progenitor cell infusion to improve the survival of mice from sepsis as well as an article by Dr Karen Litwa, East Carolina University, that explores…
New research has shown that one-time infusion of stem cells from bone marrow improves the survival of mice with sepsis.
Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
Study reveals that the HSP27 protein plays a role in regulating blood vessel leakage, providing new targets for drugs against sepsis.
Researchers have created an immune assay that can profile host immune responses to infection and is faster than current methods.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.